LTFS
ACRS icon

Ladenburg Thalmann Financial Services’s Aclaris Therapeutics ACRS Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$8K Hold
4,000
– – ﹤0.01% 4568
2019
Q3 		$4K Buy
+4,000
New +$5.67K ﹤0.01% 4743
2019
Q2 		– Sell
-22
Closed – – 5251
2019
Q1 		$0 Sell
22
-1
-4% -$7 ﹤0.01% 5192
2018
Q4 		$0 Buy
+23
New +$237 ﹤0.01% 5185
2017
Q4 		– Sell
-30
Closed -$1K – 5014
2017
Q3 		$1K Hold
30
– – ﹤0.01% 4757
2017
Q2 		$1K Buy
+30
New +$816 ﹤0.01% 4694
2016
Q4 		– Sell
-3,200
Closed -$82K – 4818
2016
Q3 		$82K Buy
+3,200
New +$67.9K ﹤0.01% 2394

Other funds holding ACRS

MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ladenburg Thalmann Financial Services's ACRS Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services held its Aclaris Therapeutics (ACRS) position steady in Q4 2019 at 4,000 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #4568.

Ladenburg Thalmann Financial Services first reported a position in ACRS in Q3 2016 and has held it in 7 quarters since. The position peaked at $82K in Q3 2016. 79 funds tracked by Wall St. Rank hold ACRS as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 4,000 shares of Aclaris Therapeutics worth $8K as of Q4 2019.
  • Ladenburg Thalmann Financial Services left its Aclaris Therapeutics share count unchanged in Q4 2019.
  • Aclaris Therapeutics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4568 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Aclaris Therapeutics in Q3 2016 and has held it in 7 quarters since.
  • Ladenburg Thalmann Financial Services's Aclaris Therapeutics position peaked at $82K in Q3 2016.
  • 79 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.